MiNK Therapeutics Inc (NAS:INKT)

Q2 2026 Mink Therapeutics Inc Earnings Call Transcript

Aug 13, 2026 / 12:30 PM GMT

Release Date Price: $11.06 (-2.68%)

Transcript 10-Q8-K

Key Points

Positve

MiNK Therapeutics Inc (INKT) initiated a randomized Phase 2 study for AGENT-797 in acute lung injury/ARDS, with first patient dosed in Ukraine and US sites expected to start enrollment in September.
Initial data from the first two treated patients showed survival to day 28, improved oxygenation, resolution of ARDS, and no serious adverse events attributed to AGENT-797.
The company established its first international paid named patient access program in Brazil, providing a new revenue stream and demonstrating the ability to deliver off-the-shelf cell therapy across borders.
AGENT-797 is an off-the-shelf allogeneic cell therapy that does not require HLA matching, apheresis, or lymphodepletion, making it logistically feasible for critical care settings.
The company reported a 77% disease control rate in PD-1 refractory gastroesophageal cancer patients treated with AGENT-797 in combination with other agents, supporting broader oncology potential.
Net loss narrowed to $3.1 million in Q2 2026 from $4.2 million in Q2 2025, reflecting improved financial discipline.
The company is planning a seamless Phase 3 study with FDA, aiming to accelerate regulatory path for AGENT-797 in ARDS.

Negative

The initial ARDS data is from only two patients in a non-comparative run-in, and the company cautions against overinterpreting these early results.
Cash position remains low at $8.8 million, which may not be sufficient to fund the full Phase 2/3 program without additional financing.
The company has not disclosed specific enrollment numbers or rates for the randomized Phase 2 study, creating uncertainty about timelines.
The paid named patient access program is not a commercial launch and may face regulatory hurdles in different countries, limiting its revenue potential.
The Phase 2 study is being conducted in Ukraine during an active conflict, which poses operational risks and could affect patient enrollment and data quality.
The company has not yet had the FDA meeting for the Phase 3 design, and the outcome could impact the development timeline.
The therapy is still investigational, and there is no approved pharmacologic therapy for ARDS, meaning the regulatory path is uncertain.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

INKT.OQ - Mink Therapeutics Inc
Q2 2026 Mink Therapeutics Inc Earnings Call
Aug 13, 2026 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to Mink Therapeutics' second quarter 2026 conference call and webcast. All participants will be in a listen-only mode until the question-and-answer session. Please note this event is being recorded.

I would now like to turn the conference over to Stephanie Pernanacar from Mink Therapeutics, Mink Investor Relations. Stephanie, please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.